anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a method destined for the detection, evaluation and management of human metabolic function by phenotypic intervention. It is supported by digital technology and IT systems and relies on the precise calculation of specific high metabolic value bioinformatics, through the development of innovative algorithms. The variables of these algorithms are deduced on the one hand through special questionnaires, tests and measurements and on the other hand with the participation of specific biological elements of human metabolic function. These data are collected and recorded automatically, in real time and telematically, in an electronic data device. Said method aims at the metabolic reprogramming of the most efficient exclusive burning of fat tissue- by regulating cellular stress accordingly, with the use of fully personalized and innovative medical and dietary interventions. It includes automated processes and tools, creating an automated decision-making system that allows the user to either self-manage their health through metabolic wellness, or to have it processed and leveraged by designated health professionals.
PROBLEM TO BE SOLVED: To obtain an inhibitor containing an oxydesberatrol as active ingredient, capable of potently inhibiting tyrosinase activity involved in melanogenesis, thus enabling skin freckles to be prevented or treated. SOLUTION: This inhibitor contains >=0.0001wt.% of an oxydesberatrol of the formula [R is CH2 CH=C(CH3 )2 , (CH2 )7 CH=CHCH2 CH=CHCH2 CH=CH2 , (CH2 )14 CH3 , etc.] as active ingredient. A skin whitening cosmetic contains 0.0001-20wt.% of this inhibitor as the essential ingredient. The compound of the formula can be obtained, for example, by purification and isolation from the extract resulted by the use of a solvent such as ether from the powder or scrapings of Artocarpus incisus belonging to the genus Artocarpus. This active ingredient can be stably formulated in cosmetics, therefore affording a wide range of various cosmetics.
Transaminase elevations have been observed in healthy volunteers who received 200 mg of VEKLURY followed by 100 mg doses for up to 10 days; the transaminase elevations were mild (Grade 1) to moderate (Grade 2) in severity and resolved upon discontinuation of VEKLURY. Transaminase elevations have also been reported in patients with COVID-19 who received VEKLURY [see Adverse Reactions (6.1)]. Because transaminase elevations have been reported as a clinical feature of COVID-19, and the incidence was similar in patients receiving placebo versus VEKLURY in clinical trials of VEKLURY, discerning the contribution of VEKLURY to transaminase elevations in patients with COVID-19 can be challenging.

Perform hepatic laboratory testing in all patients before starting VEKLURY and while receiving VEKLURY as clinically appropriate [see Dosage and Administration (2.1) and Use in Specific Populations (8.7)].

  * Consider discontinuing VEKLURY if ALT levels increase to greater than 10 times the upper limit of normal.
  * Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation.
A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
BACKGROUND AND HYPOTHESIS: Hearing voices is a common and often distressing experience for people with psychosis, and many individuals experience medication-resistant auditory verbal hallucinations (AVH). Psychosocial interventions are often employed to address distress over hearing voices. However, although links have been made between adverse social experiences and psychosis broadly, no work has yet delineated the relationship between day-to-day social stress and hallucination severity. We aimed to define that relationship in both clinical and non-clinical voice-hearers.
STUDY DESIGN: A sample of 278 participants with a history of hearing voices was selected from the Yale Control Over Perceptual Experiences (COPE) Project. They were administered self-report measures of recent stress and recent auditory experiences within a cross-sectional design. Regression models were used to evaluate whether self-reported aspects of recent stress-and social stress in particular-were related to recent frequency of and distress over hearing voices. Related demographics and clinical characteristics were included as covariates.
STUDY RESULTS: A significant relationship was observed between recent social stress and both recent frequency of and distress over hearing voices. While other aspects of recent stress were also related to recent distress over voices, social stressors uniquely predicted distress over voice-hearing, beyond the influence of other stressors. Depressive symptom severity was also related to distress over voices.
CONCLUSIONS: Results suggest that daily social stress may be an important consideration and a potential treatment target for individuals experiencing clinical distress over auditory hallucinations.
A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
While the benefits of transplantation to society are substantial, the ever-growing population of immunosuppressed recipients poses a unique challenge in development of immunization and containment strategies to protect the population from communicable pathogens and weaponized infectious agents. The immunosuppressive regimens that have allowed the emergence of successful transplant therapy not only inhibit T cell-dependent rejection but also cause systemic immunosuppression, which attenuates the response to vaccines in general and precludes the use of live attenuated vaccines. To date, there has been relatively little detailed systematic study of the immune alterations that accompany either the short- or long-term immunosuppressive regimens used in clinical organ transplantation. Despite the recent development of increasingly effective, but also increasingly complex, regimens using drugs with very distinct molecular targets, current policies on vaccination of transplant recipients are generic and remain based on old concepts rather than on any new understanding of the cellular and molecular effects of these therapies on the human immune system. This proposal seeks to improve our understanding of the biological mechanisms that underlie the distinct immunosuppressive regimens in practice today (calcineurin-inhibitor, or CNI, and sirolimus-based regimens) and in emerging regimens that employ agents with novel mechanisms of action, such as the CD28 costimulation blockers, and/or JAK3 kinase inhibitors. Such knowledge will be critical to strategies for enhancing desirable immune responses while not precipitating rejection.
OBJECTIVES: Desmopressin is widely used for nocturia in patients with nocturnal polyuria. We investigated the continuation rate and adherence for desmopressin in patients with overactive bladder and nocturia using a claims database and evaluated factors that improved adherence.
METHODS: Patients with nocturia in a Japanese claims database who started desmopressin between September 2019 and July 2021 were evaluated. Drug persistence was assessed using the Kaplan-Meier method for initial prescription of desmopressin. The proportion of days covered (PDC) was also evaluated among patients with prescription persistence. Multivariate analysis was performed using logistic regression analysis to identify factors predicting adherence to desmopressin.
RESULTS: The study included 72,888 patients entered into Japan Medical Data Center (JMDC) database between September 2019 and July 2021. For the 236 patients prescribed desmopressin formulations, mean prescription duration was 114 days. Among the total cases, 90 (38.1%) cases were prescribed only once, mean PDC was 0.60, and the number of high-adherence patients (PDC ≥ 0.80) was 108 (45.8%). Desmopressin prescription doses were fixed in 216 patients and adjusted in 20 patients. Multivariate analysis identified prescription dose adjustment for desmopressin as significantly associated with high PDC.
CONCLUSION: Desmopressin showed a 38% dropout rate after the first dose. However, high medication continuation and high medication adherence rates (PDC) could be maintained with prescription adjustments. Careful patient monitoring and appropriate adjustment of the desmopressin dosage appear to be important factors in improving nocturia.
Painful sensitivity of the hand or foot are the most common and debilitating symptoms of complex regional pain syndrome (CRPS). Physical therapy is standard treatment for CRPS, but evidence supporting its efficacy is minimal and it can be essentially impossible for CRPS patients to actively exercise the painful limb. Using the well-characterized distal tibial fracture CRPS mouse model, we compared the therapeutic effects of several weeks of daily hindlimb loading versus rotarod walking exercise. The effects of loading and exercise were evaluated by weekly testing of hind-paw withdrawal thresholds to von Frey fibers and radiant heat, as well as measurements of paw and ankle edema. At 6 weeks after fracture, the mice were killed and the ipsilateral femur, spinal cord and L4/5 dorsal root ganglia, and hind-paw skin collected for PCR assays and paw skin Immunohistochemistry evaluation. Hindlimb loading reduced hind-paw von Frey allodynia and heat hyperalgesia and edema within a week and these effects persisted for at least a week after discontinuing treatment. These therapeutic effects of loading exceeded the beneficial effects observed with rotarod walking exercise in fracture mice. Levels of nerve growth factor and transient receptor potential vanilloid 1 (TRPV1) immunostaining in the hind-paw skin were increased at 6 weeks after fracture, and both loading and exercise treatment reduced increases. Collectively, these results suggest that loading may be an effective and possibly curative treatment in CRPS patients with sensitivity in the affected limb.
Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
88 subjects will be inoculated with rhinovirus 16 via the nasal route. The subjects will be randomized 1:1 to ColdZyme® or placebo. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation. The subjects will visit the investigational clinic on 6 occasions. During these visits the subjects will leave nasal (lavage) and pharyngeal (swab) samples for quantification of virus replication. All subjects will have a diary for scoring of cold symptoms.
A partially purified plant extract for treating subjects who are hyperglycemic is provided. The partially-purified plant extract comprises a plurality of water soluble compounds having a molecular weight greater than 800 and less than 1500 grams/mole. One of the compounds in the partially-purified plant extract is the hydrolysable gallotannin known as penta-O-galloyl-D-glucose. The partially-purified plant extract is substantially free of triterpenoids, including corosolic acid and high molecular weight ellagitannins, i.e., ellagitannins having a molecular weight of greater than 1500 grams/mole. In a highly preferred embodiment, the partially purified plant extract is derived from the tropical plant  Lagerstroemia Speciosa. L , which is also known as banaba. The present invention also relates to a method of using the present partially-purified extract to treat subjects who are hyperglycemic.
Artificial modulation of ascorbate level was investigated in mice capable of de novo synthesis of ascorbate. When mice were given exogenous ascorbate or its physiological precursor, L-gulono-η-lactone, the plasma level of ascorbate was elevated substantially but immediately returned to the basal levels. Comparably, the administration of ascorbate oxidase caused a rapid disappearance of plasma ascorbate but followed by an immediate restoration of ascorbate. These results indicate the difficulties encountered in the modulation of ascorbate level in the animal. However, the circulation life of the exogenous ascorbate oxidase in the animal was successfully extended by chemical modification with methoxypolyethylene glycol. The modified enzyme retained a full activity and exerted a remarkably prolonged depletion of plasma ascorbate compared with the native enzyme. This study suggests that the chemically modified ascorbate oxidase should find many uses in the animal studies on ascorbate since it was found to deplete plasma ascorbate even in the ascorbate-synthesizing animal in the absence of dietary control. The enzyme should prove to be useful in tumor control because there are tumor systems in mice and man amenable to the manipulation of ascorbate level.
Participants allocated to this arm receive cash transfers and access to LSB curriculum training. Female cash transfer recipients attend 10 life-skills building sessions. Sessions are held weekly and are 90 minutes long. Two trained facilitators run the session for groups of 10 women over a ten-week period.
Twenty (20) persons treated for cancer of the head and neck (HNCA) with radiation therapy or chemoradiotherapy (RT/CRT) at least 5 years previously will be randomized to an 8-week program of either EMST only and Standard Care only in order to examine the impact of EMST on swallowing function. The EMST program will consist of 5 sets of 5 breaths, 5 days per week for 8 weeks at 75% of maximum expiratory strength. Patients randomized to the EMST group will use the EMST150 (product name) expiratory muscle strength trainer according to package instructions. Standard Care will include swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion. Subjects will be instructed to practice these exercises following a progressive protocol 5 days per week for 8 weeks.

All subjects will be evaluated at baseline and at the completion of their rehabilitation program. Assessment will include measurement of maximum expiratory pressure (MEP), a videofluoroscopic swallow study (VFSS) to objectively document swallow function, administration of swallow-related quality of life (QOL) questionnaires, and documentation of current diet using the International Dysphagia Diet Standardisation Initiative (IDDSI) Drink Levels and Food Levels.
The present invention is directed to a method for improving the quality of life of a patient. The method involves assessing the patient's quality of life by evaluating parameters relating to the patient's health, and assigning a score in relation to the evaluated parameters. In one version, the patient's score is compared to a standard score, and a treatment program is assigned to the patient on the basis of the comparison. The evaluated parameters may be related to the patient's mental health and physical health, and a mental health score and a physical health score can be assigned. In another version, the mental health score is compared to the physical health score, and a treatment regimen is assigned on the basis of the comparison. The method allows for improvement in quality of life of the patient by providing for a substantially objective assessment of parameters relating to the patient's health.
PURPOSE: The purpose of this study was to report a case of Tourette syndrome, exacerbated in adulthood, that was diagnosed after bilateral lens luxation and recurrent retinal detachment due to self-injury.
METHODS: This was a case report.
RESULTS: A 35-year-old man presented with a sudden abnormality in vision and bilateral lens luxation. The patient successfully underwent bilateral lens extraction and intrascleral intraocular lens fixation; however, vitreous hemorrhage and retinal detachment occurred in the left eye. The retinal detachment was caused by a giant retinal tear and retinal dialysis. Vitrectomy was performed. However, retinal detachment recurred with proliferative vitreoretinopathy. Retinal detachment subsequently occurred in the right eye. Self-injury to the eye was observed before surgical treatment. The patient was consequently diagnosed with Tourette syndrome.
CONCLUSION: Tourette syndrome, which may be accompanied by self-injurious behavior, is a disorder that typically develops in childhood but rarely exacerbates during adulthood. A diagnosis of Tourette syndrome should be considered in cases of unexplained retinal detachment with traumatic features.
The invention discloses a new use of Gypensapogenin A in preventing and curing osteoporosis. The osteoporosis is one of important diseases harming human health. With the ageing of population, patients suffering from the osteoporosis are increasingly, and thus, huge social, medical and economic burdens are brought to the whole world. Although related experts and scholars at home and abroad attach high importance to the prevention and cure of the osteoporosis, effective therapeutic drugs for treating the osteoporosis are lacking. Discovered by in vivo tests, the Gypensapogenin A disclosed by the invention is remarkable in effect of resisting the osteoporosis. Shown by test results, the Gypensapogenin A is capable of remarkably inhibiting bone transformation rate enhancement caused by ovariectomy, reducing bone destruction, and meanwhile, is capable of improving blood calcium concentration, and thereby, the improvement of the blood calcium concentration is in favor of bone deposition. The Gypensapogenin A has a therapeutic effect on the osteoporosis caused by the estrogen deficiency, and has no estrogen-like side effects.
A method and system for delivering a pharmaceutical gas to a patient. The method and system provide a known desired quantity of the pharmaceutical gas to the patient independent of the respiratory pattern of the patient. The preferred pharmaceutical gases are CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate any further delivery of the pharmaceutical gas or can activate an alarm to alert the user that the known quantity has been delivered. The system also has alarm functions to alert the user of possible malfunctions of the system.
The "Alcohol-Based Croton Peeling Formula" is a novel specific formulation to perform the phenol-croton medical peel characterized by containing alcohol. Unlike the classic formulas, still used today, it is not an emulsion, it does not contain water or soap. This facilitates preparation and use by not needing continuous stirring. Dilutions of specific concentrations of croton oil in alcohol-phenol can be easily obtained to treat each given area, by adding to a stock solution, containing phenol, alcohol and croton, the convenient amount of another (only one) Dilution of alcohol and phenol. The new formula can also be used by working directly with a solution of alcohol, phenol and croton oil at specific concentrations. (Machine-translation by Google Translate, not legally binding)
Within the broad spectrum of atrial fibrillation (AF) symptomatology, there is a striking subset of patients with predominant or even solitary nocturnal onset of the arrhythmia. This review covers AF with nocturnal onset, with the aim of defining this distinctive subgroup among patients with AF. A periodicity analysis is provided showing a clear increased onset between 10:00 pm and 7:00 am. Multiple interacting mechanisms are discussed, such as circadian modulation of electrophysiological properties, vagal tone, and sleep disorders, as well as the potential interaction and synergism between these factors, to provide a better understanding of this clinical entity. Lastly, potential therapeutic targets for AF with nocturnal onset are addressed such as upstream therapy for underlying comorbidities, type of drug and timing of drug administration and pulmonary vein isolation, ablation of the ganglionated plexus, and autonomic nervous system modulation. Understanding the underlying AF mechanisms in the individual patient with nocturnal onset will contribute to patient-specific therapy.
Pre-operative anxiety is recognised as a potential and preventable risk factor for post-operative complications. It is estimated that between 25% to 80% of patients admitted to hospital for surgery experience pre-operative anxiety, and anxiety can negatively influence patient recovery.Physiologically pre-operative anxiety can lead to autonomic dysfunction and can modify inflammatory responses, platelet activity, and immunologic functioning. The Beck Anxiety Inventory(BAI), created by Aaron T. Beck is a 21 questions multiple choice self report inventory which measures the severity of an anxiety in adults and adolescents. It has been widely used in clinical research in mental health care mainly to measure general anxiety. The total score for all 21 symptoms can range between 0 and 63 points. A total score of 0 - 7 is interpreted as "Minimal" level of anxiety, 8 - 15 as "Mild"; 16 - 25 as "Moderate" and 26 - 63 as "Severe" level of anxiety.

This study aims to compare the alleviation of Pre-operative anxiety in patients undergoing surgery with or without music.